NewAmsterdam Pharma Company N.V.
NAMS
$16.34
$0.311.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 45.56M | 33.59M | 7.42M | 6.86M | 14.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.56M | 33.59M | 7.42M | 6.86M | 14.09M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 45.56M | 33.59M | 7.42M | 6.86M | 14.09M |
| SG&A Expenses | 70.45M | 59.93M | 50.64M | 44.02M | 37.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 221.85M | 217.73M | 216.11M | 205.46M | 197.06M |
| Operating Income | -176.29M | -184.13M | -208.69M | -198.60M | -182.97M |
| Income Before Tax | -241.60M | -198.89M | -229.38M | -228.66M | -176.91M |
| Income Tax Expenses | -1.00K | 26.00K | 27.00K | 27.00K | 27.00K |
| Earnings from Continuing Operations | -241.60 | -198.92 | -229.40 | -228.69 | -176.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -241.60M | -198.92M | -229.40M | -228.69M | -176.94M |
| EBIT | -176.29M | -184.13M | -208.69M | -198.60M | -182.97M |
| EBITDA | -176.18M | -184.06M | -208.63M | -198.54M | -182.92M |
| EPS Basic | -3.64 | -3.31 | -3.70 | -3.76 | -2.15 |
| Normalized Basic EPS | -2.01 | -1.88 | -2.15 | -2.12 | -1.34 |
| EPS Diluted | -3.64 | -3.31 | -3.70 | -3.76 | -2.15 |
| Normalized Diluted EPS | -2.01 | -1.88 | -2.15 | -2.12 | -1.34 |
| Average Basic Shares Outstanding | 465.74M | 448.78M | 436.49M | 423.84M | 328.64M |
| Average Diluted Shares Outstanding | 465.74M | 448.78M | 436.49M | 423.84M | 328.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |